Jump to content

Buphenine

From Wikipedia, the free encyclopedia
(Redirected from Nylidrin)
Buphenine
Clinical data
Trade namesArlidin
Other namesNylidrin
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 4-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]propyl}phenol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.531 Edit this at Wikidata
Chemical and physical data
FormulaC19H25NO2
Molar mass299.414 g·mol−1
3D model (JSmol)
  • OC(c1ccc(O)cc1)C(NC(C)CCc2ccccc2)C

Buphenine, also known as nylidrin and sold under the brand name Arlidin, is a β2 adrenoreceptor agonist[1] that acts as a vasodilator.[2]

It was developed as a chemical derivative of oxilofrine, and first reported in the literature in 1950.[3]

See also

[edit]

References

[edit]
  1. ^ Mittag TW, Tormay A, Messenger M, Podos SM (February 1985). "Ocular hypotension in the rabbit. Receptor mechanisms of pirbuterol and nylidrin". Invest Ophthalmol Vis Sci. 26 (2): 163–9. PMID 2857689. Archived from the original on 2013-04-15.
  2. ^ Freedman L (1955). "Arlidin: a new vasodilative sympathomimetic drug". Angiology. 6 (1): 52–8. doi:10.1177/000331975500600106. PMID 14350296. S2CID 46317963.
  3. ^ Külz F, Schneider M (1950). "Über neue gefäßerweiternde Sympathomimetika" [On new vasodilative sympathomimetics]. Klin Wochenschr (in German). 28 (31–32): 535–7. doi:10.1007/BF01481535. PMID 14775050.